English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A recent surveillance study at Vanderbilt University Medical Center indicated that 8.5% of the gram-negative bacilli isolated were resistant to gentamicin. To determine what proportion of current gentamicin-resistant isolates elaborated aminoglycoside 3-V-acetyltransferase [AAC(3)-V], a probe for this gene was constructed from a 975-base-pair PstI-SalI fragment of the nonconjugative R plasmid pCER954b. This plasmid was first isolated at Vanderbilt University Medical Center from epidemic strains of Serratia marcescens. Nineteen isolates determined to produce AAC(3)-V by MIC profile all reacted with the probe. The probe did not hybridize with DNA from organisms producing 10 other aminoglycoside-modifying enzyme types. With this probe, 30 (36%) of 84 gentamicin-resistant, gram-negative bacilli elaborated AAC(3)-V. Of these 30 isolates, 25 contained a conjugative plasmid that transferred gentamicin resistance. In contrast to other medical centers, at Vanderbilt a sizable number of gentamicin-resistant, gram-negative bacilli produced AAC(3)-V. This resistance determinant, initially identified in an epidemic Serratia strain, has persisted and become incorporated into currently isolated endemic strains of gram-negative bacilli.

Construction of a probe for the aminoglycoside 3-V-acetyltransferase gene and detection of the gene among endemic clinical isolates